Similar cardiovascular outcomes between insulin detemir and insulin glargine in type 2 diabetic patients with extremely atherosclerotic cardiovascular disease risks

Endocrine Practice,Volume 26, Issue 8, Page 818-829, August 2020.

https://journals.aace.com/doi/abs/10.4158/EP-2019-0552?af=R

Source: Endocrine Practice - September 2, 2020 Category: Endocrinology Authors: Tien-Hsing Chen Chih-Ching Wang Chi-Hung Liu Ching-Chung Hsiao Szu-Tah Chen Feng-Hsuan Liu Ming-Yun Ho Yan-Rong Li Source Type: research

More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Insulin | Lantus | Levemir